Description: Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell. The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges. Nanobiotix’s novel, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.
Home Page: www.nanobiotix.com
NBTX Technical Analysis
60 rue de Wattignies
Paris,
75012
France
Phone:
33 1 40 26 04 70
Officers
| Name | Title |
|---|---|
| Mr. Laurent Levy Ph.D. | Co-Founder, Pres of the Exec. Board & CEO |
| Mr. Bart Van Rhijn | CFO & Member of Exec. Board |
| Ms. Anne-Juliette Hermant M.A. | Chief People Officer & Member of Exec. Board |
| Prof. Para Prasad Ph.D. | Co-Founder and Member of Scientific Board |
| Mr. Earl J. Bergey Ph.d. | Co-Founder |
| Mr. Alain Dostie | Chief Operating Officer |
| Ms. Kathryn M. McNeil | Sr. VP of Investor Relations |
| Mr. Brandon Owens | VP of Strategic Marketing & Corp. Communication |
| Ms. Elsa Borghi | Head of Innovation & Drug Discovery |
| Ms. Sarah Gaubert | Head of Communication & Public Affairs Department |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 73.0056 |
| Price-to-Sales TTM: | 54.2746 |
| IPO Date: | 2020-12-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 103 |